checkAd

    Lexicon Pharmaceuticals Aktie WKN: 936717 ISIN: US5288721047 Symbol: LXRX Typ: Aktie (Seite 16)

    eröffnet am 13.03.15 09:18:58 von
    • Öffentliches Profil anzeigen
    • Private Nachricht senden
    • Nutzer folgen
    • Freundesanfrage senden
    • Beiträge des Benutzers ausblenden

    neuester Beitrag 13.03.24 08:55:25 von
    • Öffentliches Profil anzeigen
    • Private Nachricht senden
    • Nutzer folgen
    • Freundesanfrage senden
    • Beiträge des Benutzers ausblenden
    Beiträge: 151
    ID: 1.209.260
    Aufrufe heute: 0
    Gesamt: 16.587
    Aktive User: 0

    Lexicon Pharmaceuticals
    ISIN: US5288723027 · WKN: A14SSK · Symbol: LXRX
    1,5600
     
    USD
    -1,27 %
    -0,0200 USD
    Letzter Kurs 29.04.24 Nasdaq

    Neuigkeiten

    Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
    29.04.24 · globenewswire
    Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
    29.04.24 · globenewswire
    Lexicon Pharmaceuticals to Host 2024 Investor Day
    18.04.24 · globenewswire
    Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    03.04.24 · globenewswire
    Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
    25.03.24 · globenewswire

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    Deciphera Pharmaceuticals
    		25,28+72,56
    CalEthos
    		4,7450+35,57
    Eliem Therapeutics
    		5,0200+26,13
    ImmunityBio
    		8,9100+21,22
    Advaxis
    		0,6650+19,82
    WertpapierKursPerf. %
    Tiziana Life Sciences
    		0,6050-18,24
    Zivo Bioscience
    		6,5500-19,14
    AEON Biopharma Registered (A)
    		3,9900-21,30
    Kiromic Biopharma
    		2,3100-25,00
    Annovis Bio
    		7,2800-59,58
    Weitere Biotechnologie Werte »

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • …
    • 16

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 13.03.15 09:18:58
      Beitrag Nr. 1 (
      49.317.791
      • Beitrag versenden
      • Beitrag melden
      • Beitrag drucken
      • auf Facebook teilen
      • auf Twitter teilen
      • Posting-Url kopieren
      )
      Bin mal dabei interessanter Wert wie ich finde, ziemilich unterbewertet.
      • 1
      • …
      • 16
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      Exelixis
      		+0,13
      Enzon Pharmaceuticals
      		-5,17
      Gilead Sciences
      		+0,86
      Geron (Delaware)
      		+9,23
      Illumina
      		+2,00
      Morphosys
      		-2,66
      Myriad Genetics
      		+8,91
      Vertex Pharmaceuticals
      		-0,32
      Novavax
      		+4,89
      Qiagen
      		+0,76

      Meistdiskutiert

      WertpapierBeiträge
      DAX
      		205
      Tesla
      		117
      Gold
      		58
      Morphosys
      		50
      Newron Pharmaceuticals
      		46
      ENDOR
      		39
      Deutsche Bank
      		35
      BrainChip Holdings
      		30
      Atos
      		29
      Deufol
      		28
      Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
      29.04.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
      29.04.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals to Host 2024 Investor Day
      18.04.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
      03.04.24 · globenewswire · Lexicon Pharmaceuticals
      Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
      25.03.24 · globenewswire · Lexicon Pharmaceuticals
      New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
      12.03.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
      11.03.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
      11.03.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
      11.03.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
      08.01.24 · globenewswire · Lexicon Pharmaceuticals
      Lexicon Pharmaceuticals Aktie WKN: 936717 ISIN: US5288721047 Symbol: LXRX Typ: Aktie